|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00287521 |
|
Date of registration:
|
03/02/2006 |
|
Primary sponsor: |
|
|
Public title:
|
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
November 2005 |
|
Target sample size:
|
87 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00287521 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Diagnosed with open-angle glaucoma (with ot without pseudoexfoliation or pigment
dispersion component) or ocular hypertension
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Under 18
- Other protocol-defined exclusion criteria may apply.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Ocular Hypertension
|
|
Open-angle Glaucoma
|
|
Intervention(s)
|
|
Drug: AL-37807 Ophthalmic Suspension, 1.0%
|
|
Drug: Latanoprost, 0.005% (Xalatan)
|
|
Drug: Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
|
|
Other: AL-37807 Vehicle
|
|
Primary Outcome(s)
|
|
Mean intra-ocular pressure (IOP) change at Day 28 from baseline (Day 0)
[Time Frame: Day 28]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|